Skip to main content

Heejae Kang MD, PhD

  • Resident, UPMC Medical Education, Pittsburgh, PA

    Education & Training

  • University of Pittsburgh, MD, 2021
  • University of Pittsburgh, PhD, 2020
  • University of California, Berkeley, BA, 2010
Representative Publications

McAuley JR, Bailey KM, Ekambaram P, Kang H, Hu D, Freeman TJ, Klei LR, Concel VJ, Hubel NE, Sekar P, Bridwell RE, Covic L, Lucas PC#, and McAllister-Lucas LM# (2018) MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types. Oncogene, 38:7384-7398

Cheng J, Klei LR, Hubel NE, Zhang M, Schairer R, Maurer LM, Klei HB, Kang, H, Concel VJ, Delekta PC, Dang EV, Mintz MA, Baens M, Cyster JG, Parameswaran N, Thome M, Lucas PC#, and McAllister-Lucas LM# (2020) GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein. J. Clin. Invest., 130:1036-1051

Cheng J, Maurer LM, Kang H, Lucas PC, McAllister-Lucas LM. Critical protein-protein interactions within the CARMA1-BCL10-MALT1 complex: Take-home points for the cell biologist. Cell Immunol. 2020 Sep;355:104158. doi: 10.1016/j.cellimm.2020.104158. Epub 2020 Jul 7. PMID: 32721634.

Weick J, Kang H, Lee L, Kuether J, Liu X, Hansen E, Kandemir U, Rollins M, Mok J. Direct measurement of tissue oxygenation as a method of diagnosis of acute compartment syndrome. J Orthop Trauma. 2016 Nov;30(11):585-591.

Research Interests

Targeting protein-protein interactions in the CARMA-BCL10-MALT1 complex for the treatment of NF-kB-addicted lymphoid malignancies

Career Advisor
Gwendolyn Sowa, MD, PhD
Thesis Advisor
Peter Lucas, MD, PhD
Cellular and Molecular Pathology
Dissertation Title

Discovery of novel small molecule inhibitors of Bcl10-MALT1 interaction for the treatment of aggressive diffuse large B-cell lymphoma.

Graduate Year
Training Start Year